Journal
NATURE BIOTECHNOLOGY
Volume 27, Issue 4, Pages 331-337Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt0409-331
Keywords
-
Categories
Ask authors/readers for more resources
Although fewer antibody fragments have entered the clinic than full-length monoclonal antibodies, proof-of-concept studies for these therapeutics remain the main hurdle.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
